1994 Fiscal Year Final Research Report Summary
Fundamental Studies on New Effective Diagnosis and Treatment for Esophageal Carcinomas by using Monoclonal Antibody and its Fragment.
| Project/Area Number |
04807096
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Kurume University |
|---|
Principal Investigator |
IRIE Hitoshi Kurume Univ.Sch.Medicine, Assistant, 医学部, 助手 (40176516)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
FUJII Teruhiko Kurume Univ.Sch.Medicine, Assistant, 医学部, 助手 (50199288)
KONAKA Toshio Kurume Univ.Sch.Medicine, Assistant, 医学部, 助手 (00195752)
TOMITA Yusuke Kurume Univ.Sch.Medicine, Assistant, 医学部, 助手 (30197933)
SHIMA Ichiro Kurume Univ.Sch.Medicine, Assistant, 医学部, 助手 (60178928)
YAMANA Hideaki Kurume Univ.Sch.Medicine, Assist Prof., 医学部, 講師 (30140669)
|
|---|
| Project Period (FY) |
1992 – 1994
|
| Keywords | Esophageal carcinoma / Monoclonal antibody / F[ab']2 / Fab / Biodistribution / Tumor imaging |
|---|
| Research Abstract |
We had produced two types of monoclonal antibodies, KYSM-1 and KIS-1, against human squamous cell carcinoma of the esophagus for quantitaive diagnosis and optimum therapy. The isotype of KYSM-1 and KIS-1 were IgM and IgG1, respectively. These two antibodies were treated by papain to get their fragment. KYSM-1 fragment F[ab']2u and KIS-1 fragment F[ab']2 and Fab were obtained.Reactivities of these fragments were analyzed by ELISR.Reactivities of all fragments were reduced after the treatment, -28% in KYSM-1 f[ab']2u, -22% in KIS-1 F[ab']2 and -60% in KIS-1 Fab. These monoclonal antibodies and their fragments were lebeled with ^<125>I or ^<131>I by the lodogen method, and each antibody was injected into nude mice with human squamous cell carcinoma of the esophagus [KE-1]. Regarding in vivo accumulation of ^<125>I - or ^<131>I - labeled antibodies, however, ^<125>I - labeled KIS-1 F[ab']2 alone showed significantly high values in the tumor at 3 days after the injection. While, ^<125>I - labeled intact KIS-1 also showed significantly high values in the tumor by 7 days. From these results, Intact KIS-1 and KIS-1 F[ab'] 2 were labeled with ^<131>I and each or both of them were injected into the tumor-bearing nude mice with a total dose of 250uCI.The most significant inhibition of the tumor growth was noted in the mixed administration of intact and fragment KIS-1.
These results suggest that the mixed administration of ^<131>I - labeled intact KIS-1 and KIS-1 F[ab']2 may provide a quantitative tumor imaging and a targeting therapy in patients with esophageal carcinoma.
|
Research Products
(12 results)
